The Spanish National Registry for Myotonic Dystrophy Type 1

NCT07385443 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-02-04

No results posted yet for this study

Summary

Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.

The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.

Conditions

Interventions

OTHER

Patient Registry

Patient Registry

Sponsors & Collaborators

  • Instituto de Investigacion Sanitaria INCLIVA

    collaborator OTHER
  • Biobizkaia

    collaborator UNKNOWN
  • Biogipuzkoa Health Research Institute

    collaborator OTHER
  • Germans Trias i Pujol Hospital

    collaborator OTHER
  • Hospital Infanta Sofia

    collaborator OTHER
  • Hospital de Basurto

    collaborator OTHER
  • Hospital Donostia

    collaborator OTHER
  • Hospital Universitario Virgen del Rocio

    collaborator UNKNOWN
  • Hospital Universitario Marqués de Valdecilla

    collaborator OTHER
  • Complejo Hospitalario Universitario de Albacete

    collaborator OTHER
  • Hospital Universitario La Fe

    collaborator OTHER
  • Hospital Univeritario Ntra. Sra. de la Candelaria

    collaborator UNKNOWN
  • Fundació Institut Germans Trias i Pujol

    lead OTHER

Principal Investigators

  • Gisela Nogales Gadea, Ph.D. · Germans Trias i Pujol Research Institute

  • Arturo Lopez Castel, Ph.D. · INCLIVA Instituto de Investigación Sanitaria

  • Virginia Arechavala-Gomeza, Ph.D. · IIS Biobizkaia

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Spain

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07385443 on ClinicalTrials.gov